Primary Aldosteronism Market Size, Status and Forecast 2018-2025 ď ľ
Published On : 15 March 2019
E-mail: help@grandresearchstore.com
Report Studies This report focuses on the global Primary Aldosteronism status, future forecast, growth opportunity, key market, and key players. The study objectives are to present the Primary Aldosteronism development in the United States, Europe, and China. Primary aldosteronism refers to the excess production of the hormone aldosterone from the adrenal glands, resulting in low renin levels. This abnormality is caused by hyperplasia or tumors. Many suffer from fatigue, potassium deficiency and high blood pressure which may cause poor vision, confusion or headaches. The treatment for hyperaldosteronism depends on the underlying cause. In people with a single benign tumor (adenoma), surgical removal (adrenalectomy) may be curative. This is usually performed laparoscopically, through several very small incisions. For people with hyperplasia of both glands, successful treatment is often achieved with spironolactone or eplerenone, drugs that block the effect of aldosterone.
E-mail: help@grandresearchstore.com
By Manufacture
Pfizer
Sun Pharmaceutical Industries
Bristol Laboratories
CMP Pharma
Koninklijke Philips
GE Healthcare
Siemens
Shimadzu Corporation
Canon E-mail: help@grandresearchstore.com
Primary Aldosteronism Market By Application 6 5 4 3 2 1 0
Application1
Application2 2018
Application3 2025
Application4
growth
E-mail: help@grandresearchstore.com
Primary Aldosteronism Market Value
CAGR 17.19% (2018 - 2023)
xx
2018
xx
2019
xx
2020
xx
2021
xx
2022
xx
2023
xx
2024
xx
2025
E-mail: help@grandresearchstore.com
Get in touch
+91 8087042414 (Asia)
+1 (646) 781 7170 (International)
www.grandresearchstore.com
help@grandresearchstore.com
Click here to know mor e about report
Follow us: